首页 > 最新文献

Gut and Liver最新文献

英文 中文
The Long Noncoding RNA DUXAP8 Facilitates the Malignant Progression of Colon Cancer via the microRNA-378a-3p/FOXQ1 Axis. 长非编码 RNA DUXAP8 通过 microRNA-378a-3p/FOXQ1 轴促进结肠癌的恶性进展
IF 3.4 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-11-20 DOI: 10.5009/gnl240178
Rui Shang, Jianqin Jin, Yuecheng Wang

Background/aims: The long noncoding RNA DUXAP8 is a pivotal regulator in cancer pathogenesis, but the molecular mechanism underlying the role of DUXAP8 in colon cancer progression is underexplored.

Methods: In addition to bioinformatic analyses, quantitative reverse transcription polymerase chain reaction (qRT-PCR) was performed to assess DUXAP8, microRNA-378a-3p, FOXQ1 expression in colon cancer tissues, and clinical data were analyzed to determine the correlation between DUXAP8 expression and colon cancer patient outcomes. Nuclear/cytoplasmic RNA fractionation was utilized to analyze the subcellular distribution of DUXAP8. Dual-luciferase and RNA immunoprecipitation assays were performed to confirm the binding of DUXAP8/FOXQ1 and microRNA-378a-3p. After cell transfection, qRT-PCR was performed to evaluate the modulatory relationship of DUXAP8/microRNA-378a-3p/FOXQ1. Cell Counting Kit-8, MTT, scratch healing, and Transwell assays were performed to evaluate the impact of DUXAP8/microRNA-378a-3p/FOXQ1 expression on colon cancer cell functions.

Results: The results revealed that the expression of DUXAP8 and FOXQ1 was upregulated in colon cancer tissues, while the expression of microRNA-378a-3p was down-regulated. The increased DUXAP8 expression was positively correlated with lymph node metastasis and TNM stage. Dual-luciferase and RNA immunoprecipitation assays demonstrated that DUXAP8 was a sponge for microRNA-378a-3p and targeted the ability of microRNA-378a-3p to regulate FOXQ1. In addition, functional experiment results revealed that overexpressed DUXAP8 facilitated the growth and migratory ability of colon cancer cells. DUXAP8 also reversed the tumor-suppressive effect of microRNA-378a-3p. However, silencing FOXQ1 could reverse the cancer-promoting effects of high DUXAP8 expression.

Conclusions: DUXAP8 expression was significantly increased in colon cancer, which was associated with lymph node metastasis and unfavorable outcomes in colon cancer patients. DUXAP8 may hasten malignant progression of colon cancer cells through its effects on microRNA-378a-3p/FOXQ1.

背景/目的:长非编码 RNA DUXAP8 是癌症发病机制中的关键调控因子,但 DUXAP8 在结肠癌进展中的作用的分子机制尚未得到充分探索:除生物信息学分析外,还进行了定量反转录聚合酶链反应(qRT-PCR)以评估结肠癌组织中 DUXAP8、microRNA-378a-3p 和 FOXQ1 的表达,并分析了临床数据以确定 DUXAP8 表达与结肠癌患者预后之间的相关性。利用核/细胞质 RNA 分馏分析了 DUXAP8 的亚细胞分布。进行了双荧光素酶和 RNA 免疫沉淀试验,以确认 DUXAP8/FOXQ1 与 microRNA-378a-3p 的结合。细胞转染后,进行 qRT-PCR 以评估 DUXAP8/microRNA-378a-3p/FOXQ1 的调节关系。结果显示,DUXAP8/microRNA-378a-3p/FOXQ1的表达对结肠癌细胞功能有影响:结果表明:结肠癌组织中 DUXAP8 和 FOXQ1 的表达上调,而 microRNA-378a-3p 的表达下调。DUXAP8表达的增加与淋巴结转移和TNM分期呈正相关。双荧光素酶和RNA免疫沉淀实验表明,DUXAP8是microRNA-378a-3p的海绵,并能靶向调节microRNA-378a-3p调节FOXQ1的能力。此外,功能实验结果显示,过表达 DUXAP8 能促进结肠癌细胞的生长和迁移能力。DUXAP8还能逆转microRNA-378a-3p的抑瘤作用。然而,沉默FOXQ1可以逆转DUXAP8高表达的促癌作用:结论:DUXAP8在结肠癌中的表达明显增加,这与淋巴结转移和结肠癌患者的不良预后有关。DUXAP8可能通过影响microRNA-378a-3p/FOXQ1加速结肠癌细胞的恶性进展。
{"title":"The Long Noncoding RNA DUXAP8 Facilitates the Malignant Progression of Colon Cancer via the microRNA-378a-3p/FOXQ1 Axis.","authors":"Rui Shang, Jianqin Jin, Yuecheng Wang","doi":"10.5009/gnl240178","DOIUrl":"https://doi.org/10.5009/gnl240178","url":null,"abstract":"<p><strong>Background/aims: </strong>The long noncoding RNA DUXAP8 is a pivotal regulator in cancer pathogenesis, but the molecular mechanism underlying the role of DUXAP8 in colon cancer progression is underexplored.</p><p><strong>Methods: </strong>In addition to bioinformatic analyses, quantitative reverse transcription polymerase chain reaction (qRT-PCR) was performed to assess DUXAP8, microRNA-378a-3p, FOXQ1 expression in colon cancer tissues, and clinical data were analyzed to determine the correlation between DUXAP8 expression and colon cancer patient outcomes. Nuclear/cytoplasmic RNA fractionation was utilized to analyze the subcellular distribution of DUXAP8. Dual-luciferase and RNA immunoprecipitation assays were performed to confirm the binding of DUXAP8/FOXQ1 and microRNA-378a-3p. After cell transfection, qRT-PCR was performed to evaluate the modulatory relationship of DUXAP8/microRNA-378a-3p/FOXQ1. Cell Counting Kit-8, MTT, scratch healing, and Transwell assays were performed to evaluate the impact of DUXAP8/microRNA-378a-3p/FOXQ1 expression on colon cancer cell functions.</p><p><strong>Results: </strong>The results revealed that the expression of DUXAP8 and FOXQ1 was upregulated in colon cancer tissues, while the expression of microRNA-378a-3p was down-regulated. The increased DUXAP8 expression was positively correlated with lymph node metastasis and TNM stage. Dual-luciferase and RNA immunoprecipitation assays demonstrated that DUXAP8 was a sponge for microRNA-378a-3p and targeted the ability of microRNA-378a-3p to regulate FOXQ1. In addition, functional experiment results revealed that overexpressed DUXAP8 facilitated the growth and migratory ability of colon cancer cells. DUXAP8 also reversed the tumor-suppressive effect of microRNA-378a-3p. However, silencing FOXQ1 could reverse the cancer-promoting effects of high DUXAP8 expression.</p><p><strong>Conclusions: </strong>DUXAP8 expression was significantly increased in colon cancer, which was associated with lymph node metastasis and unfavorable outcomes in colon cancer patients. DUXAP8 may hasten malignant progression of colon cancer cells through its effects on microRNA-378a-3p/FOXQ1.</p>","PeriodicalId":12885,"journal":{"name":"Gut and Liver","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rebamipide Prevents the Hemoglobin Drop Related to Mucosal-Damaging Agents at a Level Comparable to Proton Pump Inhibitors. 雷巴米特能防止与粘膜损伤剂有关的血红蛋白下降,其水平与质子泵抑制剂相当。
IF 3.4 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-11-15 Epub Date: 2024-03-12 DOI: 10.5009/gnl230372
Ji Eun Kim, Yeong Chan Lee, Tae Se Kim, Eun Ran Kim, Sung Noh Hong, Young-Ho Kim, Kyunga Kim, Dong Kyung Chang

Background/aims: : The effect of proton pump inhibitors (PPIs) on the lower gastrointestinal (GI) tract is uncertain, with potential to worsen damage. This study aimed to find the best method for protecting the entire GI tract from mucosal damage.

Methods: : A retrospective cohort study at Samsung Medical Center (2002-2019) included 195,817 patients prescribed GI mucosa-damaging agents. The primary goal was to assess the effectiveness of GI protective agents in preventing significant hemoglobin drops (>2 g/dL), indicating overall GI mucosal damage. Self-controlled case series and landmark analysis were used to address biases in real-world data.

Results: : The incidence rate ratios for rebamipide, PPI, and histamine-2 receptor antagonist (H2RA) were 0.34, 0.33, and 0.52, respectively. Rebamipide showed a significantly lower incidence rate than H2RA and was comparable to PPIs. Landmark analysis revealed significant reductions in hemoglobin drop risk with rebamipide and H2RA, but not with PPI.

Conclusions: : Rebamipide, like PPIs, was highly effective in preventing blood hemoglobin level decreases, as shown in real-world data. Rebamipide could be a comprehensive strategy for protecting the entire GI tract, especially when considering PPIs' potential side effects on the lower GI tract.

背景/目的质子泵抑制剂(PPI)对下胃肠道(GI)的影响尚不确定,有可能加重损伤。本研究旨在找到保护整个胃肠道免受粘膜损伤的最佳方法:三星医疗中心的一项回顾性队列研究(2002-2019 年)纳入了 195,817 名开具消化道粘膜损伤药物处方的患者。主要目的是评估胃肠道保护剂在防止血红蛋白显著下降(>2 g/dL)方面的有效性,血红蛋白下降表明胃肠道粘膜整体受损。采用自我对照病例系列和地标分析来解决现实世界数据中的偏差问题:瑞巴咪肽、PPI 和组胺-2 受体拮抗剂 (H2RA) 的发病率比分别为 0.34、0.33 和 0.52。瑞巴派特的发病率明显低于 H2RA,与 PPIs 不相上下。地标分析显示,瑞巴咪啶和 H2RA 能显著降低血红蛋白下降的风险,而 PPI 则不能:结论:与 PPIs 一样,瑞巴派特也能有效防止血红蛋白水平下降。特别是考虑到 PPIs 对下消化道的潜在副作用,瑞巴派特可作为保护整个消化道的综合策略。
{"title":"Rebamipide Prevents the Hemoglobin Drop Related to Mucosal-Damaging Agents at a Level Comparable to Proton Pump Inhibitors.","authors":"Ji Eun Kim, Yeong Chan Lee, Tae Se Kim, Eun Ran Kim, Sung Noh Hong, Young-Ho Kim, Kyunga Kim, Dong Kyung Chang","doi":"10.5009/gnl230372","DOIUrl":"10.5009/gnl230372","url":null,"abstract":"<p><strong>Background/aims: </strong>: The effect of proton pump inhibitors (PPIs) on the lower gastrointestinal (GI) tract is uncertain, with potential to worsen damage. This study aimed to find the best method for protecting the entire GI tract from mucosal damage.</p><p><strong>Methods: </strong>: A retrospective cohort study at Samsung Medical Center (2002-2019) included 195,817 patients prescribed GI mucosa-damaging agents. The primary goal was to assess the effectiveness of GI protective agents in preventing significant hemoglobin drops (>2 g/dL), indicating overall GI mucosal damage. Self-controlled case series and landmark analysis were used to address biases in real-world data.</p><p><strong>Results: </strong>: The incidence rate ratios for rebamipide, PPI, and histamine-2 receptor antagonist (H2RA) were 0.34, 0.33, and 0.52, respectively. Rebamipide showed a significantly lower incidence rate than H2RA and was comparable to PPIs. Landmark analysis revealed significant reductions in hemoglobin drop risk with rebamipide and H2RA, but not with PPI.</p><p><strong>Conclusions: </strong>: Rebamipide, like PPIs, was highly effective in preventing blood hemoglobin level decreases, as shown in real-world data. Rebamipide could be a comprehensive strategy for protecting the entire GI tract, especially when considering PPIs' potential side effects on the lower GI tract.</p>","PeriodicalId":12885,"journal":{"name":"Gut and Liver","volume":" ","pages":"1026-1036"},"PeriodicalIF":3.4,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11565003/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140101355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bismuth-Based Quadruple Therapy as First-Line Treatment for Clarithromycin-Resistant Helicobacter pylori Infection: A Prospective Randomized Comparison of 7- and 14-Day Treatment Regimens. 基于铋的四联疗法作为克拉霉素耐药幽门螺旋杆菌感染的一线治疗方法:7 天和 14 天治疗方案的前瞻性随机比较。
IF 3.4 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-11-15 Epub Date: 2024-05-07 DOI: 10.5009/gnl230453
Chul-Hyun Lim, Jung-Hwan Oh

Background/aims: : Bismuth-based quadruple therapy (BQT) is a treatment option for clarithromycin-resistant Helicobacter pylori (HP) infection. The aim of this study was to compare the efficacy of 7-day BQT with that of 14-day BQT as first-line treatment for clarithromycin-resistant HP infection.

Methods: : A total of 162 treatment-naïve patients with peptic ulcer disease and clarithromycin-resistant HP infection confirmed by real-time polymerase chain reaction (RT-PCR) were enrolled. The enrolled patients were prospectively randomized to receive BQT for either 7 or 14 days of treatment. Eradication of HP infection was assessed using a 13C-urea breath test. Eradication and adverse event rates of the two groups were assessed.

Results: : The overall eradication rates in the intention-to-treat (ITT) and per-protocol (PP) analyses were 83.0% (95% confidence interval [CI], 77.2% to 88.9%; 132/159) and 89.8% (95% CI, 84.9% to 94.7%; 132/147), respectively. The eradication rates in the ITT analysis were 79.0% (64/81) in the 7-day group and 87.2% (68/78) in the 14-day group (p=0.170). The eradication rates in the PP analysis were 86.5% (64/74) in the 7-day group and 93.2% (68/73) in the 14-day group (p=0.182). Clinically significant adverse events occurred in 18.2% of patients. There was no statistically significant difference in the rates of individual or all adverse events between the two groups.

Conclusions: : Both 7-day and 14-day BQT were effective and safe as first-line therapy for HP infections identified as resistant to clarithromycin by RT-PCR. For clarithromycin-resistant HP infections, 7-day BQT may be sufficient as first-line therapy.

背景/目的::铋剂四联疗法(BQT)是治疗耐克拉霉素幽门螺旋杆菌(HP)感染的一种方法。本研究旨在比较 7 天 BQT 和 14 天 BQT 作为耐克拉霉素幽门螺杆菌感染一线治疗的疗效:共有162名消化性溃疡病且经实时聚合酶链式反应(RT-PCR)证实耐克拉霉素的HP感染者被纳入研究。入组患者被前瞻性地随机分配接受 BQT 7 天或 14 天的治疗。通过13C-尿素呼气试验评估HP感染的根除情况。对两组患者的根除率和不良反应率进行评估:在意向治疗(ITT)和每方案(PP)分析中,总根除率分别为83.0%(95%置信区间[CI],77.2%至88.9%;132/159)和89.8%(95%置信区间,84.9%至94.7%;132/147)。在 ITT 分析中,7 天组的根除率为 79.0%(64/81),14 天组的根除率为 87.2%(68/78)(P=0.170)。在 PP 分析中,7 天组的根除率为 86.5%(64/74),14 天组为 93.2%(68/73)(P=0.182)。18.2%的患者出现了临床重大不良反应。两组患者的单个或所有不良事件发生率无统计学差异:结论:7天和14天BQT作为一线疗法治疗通过RT-PCR鉴定为对克拉霉素耐药的HP感染既有效又安全。对于克拉霉素耐药的HP感染,7天BQT作为一线疗法可能就足够了。
{"title":"Bismuth-Based Quadruple Therapy as First-Line Treatment for Clarithromycin-Resistant <i>Helicobacter pylori</i> Infection: A Prospective Randomized Comparison of 7- and 14-Day Treatment Regimens.","authors":"Chul-Hyun Lim, Jung-Hwan Oh","doi":"10.5009/gnl230453","DOIUrl":"10.5009/gnl230453","url":null,"abstract":"<p><strong>Background/aims: </strong>: Bismuth-based quadruple therapy (BQT) is a treatment option for clarithromycin-resistant <i>Helicobacter pylori</i> (HP) infection. The aim of this study was to compare the efficacy of 7-day BQT with that of 14-day BQT as first-line treatment for clarithromycin-resistant HP infection.</p><p><strong>Methods: </strong>: A total of 162 treatment-naïve patients with peptic ulcer disease and clarithromycin-resistant HP infection confirmed by real-time polymerase chain reaction (RT-PCR) were enrolled. The enrolled patients were prospectively randomized to receive BQT for either 7 or 14 days of treatment. Eradication of HP infection was assessed using a <sup>13</sup>C-urea breath test. Eradication and adverse event rates of the two groups were assessed.</p><p><strong>Results: </strong>: The overall eradication rates in the intention-to-treat (ITT) and per-protocol (PP) analyses were 83.0% (95% confidence interval [CI], 77.2% to 88.9%; 132/159) and 89.8% (95% CI, 84.9% to 94.7%; 132/147), respectively. The eradication rates in the ITT analysis were 79.0% (64/81) in the 7-day group and 87.2% (68/78) in the 14-day group (p=0.170). The eradication rates in the PP analysis were 86.5% (64/74) in the 7-day group and 93.2% (68/73) in the 14-day group (p=0.182). Clinically significant adverse events occurred in 18.2% of patients. There was no statistically significant difference in the rates of individual or all adverse events between the two groups.</p><p><strong>Conclusions: </strong>: Both 7-day and 14-day BQT were effective and safe as first-line therapy for HP infections identified as resistant to clarithromycin by RT-PCR. For clarithromycin-resistant HP infections, 7-day BQT may be sufficient as first-line therapy.</p>","PeriodicalId":12885,"journal":{"name":"Gut and Liver","volume":" ","pages":"970-976"},"PeriodicalIF":3.4,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11564998/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140854837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thickened Gastric Wall: Simplifying the Diagnosis. 胃壁增厚:简化诊断。
IF 3.4 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-11-15 DOI: 10.5009/gnl240500
Joon Sung Kim, Jong Yeul Lee
{"title":"Thickened Gastric Wall: Simplifying the Diagnosis.","authors":"Joon Sung Kim, Jong Yeul Lee","doi":"10.5009/gnl240500","DOIUrl":"10.5009/gnl240500","url":null,"abstract":"","PeriodicalId":12885,"journal":{"name":"Gut and Liver","volume":"18 6","pages":"929-930"},"PeriodicalIF":3.4,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11565000/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142618776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metal Stents for the Management of Massive Hemobilia in Patients with Hilum-Involving Cholangiocarcinoma Receiving Multi-Regimen Chemotherapy. 金属支架用于治疗接受多方案化疗的肝门部胆管癌患者的大量出血。
IF 4.3 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-11-15 Epub Date: 2024-11-07 DOI: 10.5009/gnl240087
Seung Yeon Lee, Min Je Sung, Suk Pyo Shin, Hong Jae Chon, Beodeul Kang, Kwang Hyun Ko, Mamoru Takenaka, Chang-Il Kwon

Recent clinical outcomes of multi-regimen chemotherapy in patients with cholangiocarcinoma (CCC) have shown benefits in terms of overall survival. However, repeated endoscopic biliary drainage (EBD) and serious adverse events negatively affect prolongation of the survival period. The aim of this study was to investigate the prevalence of massive hemobilia and the outcomes of its management with fully covered self-expandable metal stents (FC-SEMSs) in patients with hilum-involving CCC receiving multi-regimen chemotherapy. The methods and effects of FC-SEMS placement were retrospectively investigated following the occurrence of massive hemobilia during EBD. A total of 356 patients with CCC received multi-regimen chemotherapy. Among them, 181 patients had hilar invasion, and seven patients (3.9%) developed massive hemobilia during repeated EBD using removable stents. In all cases, the tumor encased the right hepatic artery. In six patients (85.7%), hemostasis was immediately and completely achieved by inserting one or two FC-SEMSs proximal to the hilar invasion area. Therefore, if the tumor encases the right hepatic artery, massive hemobilia is likely to occur during multi-regimen chemotherapy. Thus, prompt placement of a FC-SEMS would be an effective treatment option for massive hemobilia in patients with hilum-involving CCC.

对胆管癌(CCC)患者进行多方案化疗的最新临床结果显示,患者的总生存期有所延长。然而,反复内镜胆道引流术(EBD)和严重不良事件对生存期的延长产生了负面影响。本研究旨在调查接受多方案化疗的肝门部受累 CCC 患者中大量血肿的发生率以及使用全覆盖自膨胀金属支架(FC-SEMS)治疗的效果。在 EBD 期间发生大出血后,我们对放置 FC-SEMS 的方法和效果进行了回顾性研究。共有356名CCC患者接受了多方案化疗。其中,181 例患者有肺门侵犯,7 例患者(3.9%)在使用可拆卸支架反复进行 EBD 期间出现大量出血。在所有病例中,肿瘤都包裹着右肝动脉。在六名患者(85.7%)中,通过在肝门侵犯区域近端插入一个或两个 FC-SEMS 即刻完全止血。因此,如果肿瘤包绕右肝动脉,在多方案化疗期间很可能会出现大量出血。因此,对于肝门受侵的 CCC 患者,及时置入 FC-SEMS 将是治疗大量出血的有效方法。
{"title":"Metal Stents for the Management of Massive Hemobilia in Patients with Hilum-Involving Cholangiocarcinoma Receiving Multi-Regimen Chemotherapy.","authors":"Seung Yeon Lee, Min Je Sung, Suk Pyo Shin, Hong Jae Chon, Beodeul Kang, Kwang Hyun Ko, Mamoru Takenaka, Chang-Il Kwon","doi":"10.5009/gnl240087","DOIUrl":"10.5009/gnl240087","url":null,"abstract":"<p><p>Recent clinical outcomes of multi-regimen chemotherapy in patients with cholangiocarcinoma (CCC) have shown benefits in terms of overall survival. However, repeated endoscopic biliary drainage (EBD) and serious adverse events negatively affect prolongation of the survival period. The aim of this study was to investigate the prevalence of massive hemobilia and the outcomes of its management with fully covered self-expandable metal stents (FC-SEMSs) in patients with hilum-involving CCC receiving multi-regimen chemotherapy. The methods and effects of FC-SEMS placement were retrospectively investigated following the occurrence of massive hemobilia during EBD. A total of 356 patients with CCC received multi-regimen chemotherapy. Among them, 181 patients had hilar invasion, and seven patients (3.9%) developed massive hemobilia during repeated EBD using removable stents. In all cases, the tumor encased the right hepatic artery. In six patients (85.7%), hemostasis was immediately and completely achieved by inserting one or two FC-SEMSs proximal to the hilar invasion area. Therefore, if the tumor encases the right hepatic artery, massive hemobilia is likely to occur during multi-regimen chemotherapy. Thus, prompt placement of a FC-SEMS would be an effective treatment option for massive hemobilia in patients with hilum-involving CCC.</p>","PeriodicalId":12885,"journal":{"name":"Gut and Liver","volume":" ","pages":"1085-1089"},"PeriodicalIF":4.3,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11565014/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142590351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cognitive Impairment and Insomnia in Celiac Disease: A Systematic Review and Meta-Analysis. 乳糜泻患者的认知障碍和失眠:系统回顾与元分析》。
IF 3.4 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-11-15 Epub Date: 2024-08-01 DOI: 10.5009/gnl240063
Renato Beas, Ambar Godoy, Dalton A Norwood, Ysaith Orellana Ascencio, Diego Izquierdo-Veraza, Eleazar E Montalvan-Sanchez, Mirian Ramirez, Satya Kurada

Emerging evidence suggests a broader spectrum of celiac disease (CeD) system involvement, including neurological manifestations. We aimed to conduct a systematic review and meta-analysis of the available evidence from studies assessing the association of cognitive impairment and insomnia with CeD. A total of 259 participants with CeD were included in the studies investigating insomnia and 179 were included in studies investigating cognitive impairment. The overall pooled odds ratio for insomnia in patients with CeD was 1.83 (95% confidence interval, 1.38 to 2.42; I2=0.00%). The present study provides valuable insights into the available evidence from studies investigating cognitive impairment in patients with CeD and our systematic review and metaanalysis revealed a significant association between CeD and insomnia.

新的证据表明,乳糜泻(CeD)系统受累的范围更广,包括神经系统表现。我们旨在对评估认知障碍和失眠与乳糜泻相关性的研究中的现有证据进行系统回顾和荟萃分析。调查失眠的研究共纳入了 259 名 CeD 患者,调查认知障碍的研究共纳入了 179 名 CeD 患者。CeD患者失眠的总合几率比为1.83(95%置信区间为1.38至2.42;I2=0.00%)。本研究为研究 CeD 患者认知障碍的现有证据提供了宝贵的见解,我们的系统综述和荟萃分析表明 CeD 与失眠之间存在显著关联。
{"title":"Cognitive Impairment and Insomnia in Celiac Disease: A Systematic Review and Meta-Analysis.","authors":"Renato Beas, Ambar Godoy, Dalton A Norwood, Ysaith Orellana Ascencio, Diego Izquierdo-Veraza, Eleazar E Montalvan-Sanchez, Mirian Ramirez, Satya Kurada","doi":"10.5009/gnl240063","DOIUrl":"10.5009/gnl240063","url":null,"abstract":"<p><p>Emerging evidence suggests a broader spectrum of celiac disease (CeD) system involvement, including neurological manifestations. We aimed to conduct a systematic review and meta-analysis of the available evidence from studies assessing the association of cognitive impairment and insomnia with CeD. A total of 259 participants with CeD were included in the studies investigating insomnia and 179 were included in studies investigating cognitive impairment. The overall pooled odds ratio for insomnia in patients with CeD was 1.83 (95% confidence interval, 1.38 to 2.42; I<sup>2</sup>=0.00%). The present study provides valuable insights into the available evidence from studies investigating cognitive impairment in patients with CeD and our systematic review and metaanalysis revealed a significant association between CeD and insomnia.</p>","PeriodicalId":12885,"journal":{"name":"Gut and Liver","volume":" ","pages":"1080-1084"},"PeriodicalIF":3.4,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11564999/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141859489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Differential Diagnosis of Thickened Gastric Wall between Hypertrophic Gastritis and Borrmann Type 4 Advanced Gastric Cancer. 增厚性胃炎与Borrmann 4型晚期胃癌的鉴别诊断。
IF 3.4 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-11-15 Epub Date: 2023-11-28 DOI: 10.5009/gnl230307
Jun-Young Seo, Do Hoon Kim, Ji Yong Ahn, Kee Don Choi, Hwa Jung Kim, Hee Kyong Na, Jeong Hoon Lee, Kee Wook Jung, Ho June Song, Gin Hyug Lee, Hwoon-Yong Jung

Background/aims: : Accurately diagnosing diffuse gastric wall thickening is challenging. Hypertrophic gastritis (HG), while benign, mimics the morphology of Borrmann type 4 advanced gastric cancer (AGC B-4). We compared the features of endoscopy and endoscopic ultrasonography (EUS) between them.

Methods: : We retrospectively reviewed patients who underwent EUS for gastric wall thickening between 2000 and 2021, selecting HG and pathologically confirmed advanced gastric cancer cases. Ulceration and antral wall thickening were determined via endoscopy, while EUS assessed the 5-layered gastric wall structure, measuring the proper muscle (PM) layer and total wall thickness.

Results: : Male dominance was observed in AGC B-4, and the hemoglobin and albumin levels were significantly lower. The rate of antral wall thickening and presence of ulceration were significantly higher in AGC B-4 cases. Destruction of the PM layers was observed only in AGC B-4 cases, and the PM was significantly thicker in AGC B-4 cases. Forceps biopsy had an excellent success rate in ulcer-present AGC B-4 cases, but only a 42.6% success rate was observed for cases without ulcers, necessitating additional diagnostic modalities. A PM thickness of 2.39 mm distinguished between AGC B-4 and HG effectively. The multivariable analysis showed that a thickened PM layer and the presence of ulceration were significant risk factors for the diagnosis of AGC B-4.

Conclusions: : Endoscopic findings of a thickened gastric wall, including antral involvement, and presence of ulcer were significant risk factors for the diagnosis of AGC B-4. EUS findings of destroyed wall layers and a thickened PM of >2.39 mm were the key points of differentiation between HG and AGC B-4.

背景/目的:准确诊断弥漫性胃壁增厚具有挑战性。肥厚性胃炎(HG)虽然是良性的,但其形态与Borrmann 4型晚期胃癌(AGC B-4)相似。我们比较了内窥镜检查和超声检查的特点。方法:我们回顾性分析2000年至2021年间接受EUS治疗的胃壁增厚患者,选择HG和病理证实的晚期胃癌病例。胃镜检查溃疡和胃壁增厚,EUS评估胃壁5层结构,测量适当肌层(PM)和总壁厚。结果:AGC B-4呈男性显性,血红蛋白和白蛋白水平明显降低。胃壁增厚和溃疡的发生率在AGC B-4病例中明显更高。仅在AGC B-4病例中观察到PM层的破坏,并且在AGC B-4病例中PM明显变厚。在存在溃疡的AGC B-4病例中,钳活检的成功率很高,但在没有溃疡的病例中,仅观察到42.6%的成功率,需要额外的诊断方式。PM厚度为2.39 mm,可有效区分AGC B-4和HG。多变量分析显示,PM层增厚和溃疡的存在是诊断AGC B-4的重要危险因素。结论:胃镜检查发现胃壁增厚,包括胃窦受累和溃疡的存在是诊断AGC B-4的重要危险因素。EUS表现为细胞壁破坏,PM增厚>2.39 mm,是HG与AGC B-4鉴别的关键。
{"title":"Differential Diagnosis of Thickened Gastric Wall between Hypertrophic Gastritis and Borrmann Type 4 Advanced Gastric Cancer.","authors":"Jun-Young Seo, Do Hoon Kim, Ji Yong Ahn, Kee Don Choi, Hwa Jung Kim, Hee Kyong Na, Jeong Hoon Lee, Kee Wook Jung, Ho June Song, Gin Hyug Lee, Hwoon-Yong Jung","doi":"10.5009/gnl230307","DOIUrl":"10.5009/gnl230307","url":null,"abstract":"<p><strong>Background/aims: </strong>: Accurately diagnosing diffuse gastric wall thickening is challenging. Hypertrophic gastritis (HG), while benign, mimics the morphology of Borrmann type 4 advanced gastric cancer (AGC B-4). We compared the features of endoscopy and endoscopic ultrasonography (EUS) between them.</p><p><strong>Methods: </strong>: We retrospectively reviewed patients who underwent EUS for gastric wall thickening between 2000 and 2021, selecting HG and pathologically confirmed advanced gastric cancer cases. Ulceration and antral wall thickening were determined via endoscopy, while EUS assessed the 5-layered gastric wall structure, measuring the proper muscle (PM) layer and total wall thickness.</p><p><strong>Results: </strong>: Male dominance was observed in AGC B-4, and the hemoglobin and albumin levels were significantly lower. The rate of antral wall thickening and presence of ulceration were significantly higher in AGC B-4 cases. Destruction of the PM layers was observed only in AGC B-4 cases, and the PM was significantly thicker in AGC B-4 cases. Forceps biopsy had an excellent success rate in ulcer-present AGC B-4 cases, but only a 42.6% success rate was observed for cases without ulcers, necessitating additional diagnostic modalities. A PM thickness of 2.39 mm distinguished between AGC B-4 and HG effectively. The multivariable analysis showed that a thickened PM layer and the presence of ulceration were significant risk factors for the diagnosis of AGC B-4.</p><p><strong>Conclusions: </strong>: Endoscopic findings of a thickened gastric wall, including antral involvement, and presence of ulcer were significant risk factors for the diagnosis of AGC B-4. EUS findings of destroyed wall layers and a thickened PM of >2.39 mm were the key points of differentiation between HG and AGC B-4.</p>","PeriodicalId":12885,"journal":{"name":"Gut and Liver","volume":" ","pages":"961-969"},"PeriodicalIF":3.4,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11565008/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138444467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk Assessment of Metachronous Gastric Neoplasm after Endoscopic Resection for Early Gastric Cancer According to Age at Helicobacter pylori Eradication. 根据幽门螺杆菌根除年龄评估早期胃癌内镜下切除术后并发胃肿瘤的风险
IF 3.4 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-11-15 Epub Date: 2024-03-21 DOI: 10.5009/gnl230383
Seunghan Lee, Soo-Jeong Cho, Hyunsoo Chung, Bokyung Kim, Mi Jin Oh, Yun Suk Na, Jun Hee Lee, Jiyoon Kim, Sang Gyun Kim

Background/aims: Helicobacter pylori eradication can reduce the incidence of metachronous gastric neoplasm (MGN) after endoscopic submucosal dissection (ESD) for early gastric cancer (EGC). This study evaluated the risk of developing MGN after ESD for EGC based on age at H. pylori eradication.

Methods: Data of patients who underwent curative ESD for EGC with H. pylori infection between 2005 and 2018 were retrospectively analyzed. The patients were allocated to four groups according to age at H. pylori eradication: group 1 (<50 years), group 2 (50-59 years), group 3 (60-69 years), and group 4 (≥70 years).

Results: All patients were followed up for at least 5 years after ESD. The 5-year cumulative incidence of MGN was 2.1%, 7.0%, 8.7%, and 16.7% in groups 1, 2, 3, and 4, respectively (p<0.001), and groups 3 and 4 showed a significant increase in the risk of MGN (hazard ratio [HR], 4.66; 95% confidence interval [CI], 1.09 to 19.92 and HR, 10.75; 95% CI, 2.45 to 47.12). After adjustments for moderate to severe intestinal metaplasia based on the updated Sydney system, groups 3 and 4 remained significantly associated with MGN (HR, 4.40; 95% CI, 1.03 to 18.84 and HR, 10.14; 95% CI, 2.31 to 44.57).

Conclusions: The incidence of MGN after ESD for EGC increased with age at H. pylori eradication. Age at H. pylori eradication ≥60 years was an independent risk factor for MGN, even after adjusting for the presence of advanced intestinal metaplasia.

背景/目的:根除幽门螺杆菌可降低早期胃癌(ESC)内镜黏膜下剥离术(ESD)后并发胃肿瘤(MGN)的发生率。本研究根据根除幽门螺杆菌时的年龄,评估了ESD治疗EGC后罹患MGN的风险:方法:回顾性分析了2005年至2018年间因幽门螺杆菌感染接受根治性ESD治疗EGC的患者数据。根据幽门螺杆菌根除时的年龄,将患者分为四组:第一组(结果:第一组患者的幽门螺杆菌根除率为100%;第二组患者的幽门螺杆菌根除率为100%;第三组患者的幽门螺杆菌根除率为100%;第四组患者的幽门螺杆菌根除率为100%:所有患者均在ESD后接受了至少5年的随访。第1组、第2组、第3组和第4组的MGN 5年累计发病率分别为2.1%、7.0%、8.7%和16.7%(结论:ESD术后MGN的发病率与ESD术后幽门螺杆菌根除的年龄有关:ESD治疗EGC后MGN的发生率随幽门螺杆菌根除年龄的增加而增加。幽门螺杆菌根除年龄≥60岁是MGN的独立风险因素,即使在调整了是否存在晚期肠化生之后也是如此。
{"title":"Risk Assessment of Metachronous Gastric Neoplasm after Endoscopic Resection for Early Gastric Cancer According to Age at <i>Helicobacter pylori</i> Eradication.","authors":"Seunghan Lee, Soo-Jeong Cho, Hyunsoo Chung, Bokyung Kim, Mi Jin Oh, Yun Suk Na, Jun Hee Lee, Jiyoon Kim, Sang Gyun Kim","doi":"10.5009/gnl230383","DOIUrl":"10.5009/gnl230383","url":null,"abstract":"<p><strong>Background/aims: </strong><i>Helicobacter pylori</i> eradication can reduce the incidence of metachronous gastric neoplasm (MGN) after endoscopic submucosal dissection (ESD) for early gastric cancer (EGC). This study evaluated the risk of developing MGN after ESD for EGC based on age at <i>H. pylori</i> eradication.</p><p><strong>Methods: </strong>Data of patients who underwent curative ESD for EGC with <i>H. pylori</i> infection between 2005 and 2018 were retrospectively analyzed. The patients were allocated to four groups according to age at <i>H. pylori</i> eradication: group 1 (<50 years), group 2 (50-59 years), group 3 (60-69 years), and group 4 (≥70 years).</p><p><strong>Results: </strong>All patients were followed up for at least 5 years after ESD. The 5-year cumulative incidence of MGN was 2.1%, 7.0%, 8.7%, and 16.7% in groups 1, 2, 3, and 4, respectively (p<0.001), and groups 3 and 4 showed a significant increase in the risk of MGN (hazard ratio [HR], 4.66; 95% confidence interval [CI], 1.09 to 19.92 and HR, 10.75; 95% CI, 2.45 to 47.12). After adjustments for moderate to severe intestinal metaplasia based on the updated Sydney system, groups 3 and 4 remained significantly associated with MGN (HR, 4.40; 95% CI, 1.03 to 18.84 and HR, 10.14; 95% CI, 2.31 to 44.57).</p><p><strong>Conclusions: </strong>The incidence of MGN after ESD for EGC increased with age at <i>H. pylori</i> eradication. Age at <i>H. pylori</i> eradication ≥60 years was an independent risk factor for MGN, even after adjusting for the presence of advanced intestinal metaplasia.</p>","PeriodicalId":12885,"journal":{"name":"Gut and Liver","volume":" ","pages":"992-1001"},"PeriodicalIF":3.4,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11565006/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140174265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cellular Plasticity in Gut and Liver Regeneration. 肠道和肝脏再生中的细胞可塑性
IF 3.4 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-11-15 Epub Date: 2024-07-31 DOI: 10.5009/gnl240005
Minwook Kim, Yoojeong Park, You Sun Kim, Sungjin Ko

The intestine and liver share a unique regenerative property that sets them apart from other mammalian visceral organs. The intestinal epithelium exhibits rapid renewal, making it one of the fastest renewing tissues in humans. Under physiological conditions, intestinal stem cells within each intestinal crypt continuously differentiate into the different types of intestinal epithelial cells to maintain intestinal homeostasis. However, when exposed to tissue damage or stressful conditions such as inflammation, intestinal epithelial cells in the gastrointestinal tract exhibit plasticity, allowing fully differentiated cells to regain their stem cell properties. Likewise, hepatic epithelial cells possess a remarkable regenerative capacity to restore lost liver mass through proliferation-mediated liver regeneration. When the proliferation-mediated regenerative capacity is impaired, hepatocytes and biliary epithelial cells (BECs) can undergo plasticity-mediated regeneration and replenish each other. The transition of mammalian liver progenitor cells to hepatocytes/BECs can be observed under tightly controlled experimental conditions such as severe hepatocyte injury accompanied by the loss of regenerative capacity. In this review, we will discuss the mechanism by which cellular plasticity contributes to the regeneration process and the potential therapeutic implications of understanding and harnessing cellular plasticity in the gut and liver.

肠道和肝脏具有独特的再生特性,这使它们有别于其他哺乳动物的内脏器官。肠上皮细胞更新迅速,是人类更新最快的组织之一。在生理条件下,每个肠隐窝中的肠干细胞会不断分化成不同类型的肠上皮细胞,以维持肠道的平衡。然而,当受到组织损伤或炎症等压力条件时,胃肠道中的肠上皮细胞会表现出可塑性,使完全分化的细胞恢复其干细胞特性。同样,肝上皮细胞具有显著的再生能力,可通过增殖介导的肝脏再生恢复失去的肝脏质量。当增殖介导的再生能力受损时,肝细胞和胆道上皮细胞(BECs)可进行可塑性介导的再生,并相互补充。哺乳动物肝脏祖细胞向肝细胞/胆道上皮细胞的转变可在严格控制的实验条件下观察到,如严重的肝细胞损伤伴随着再生能力的丧失。在这篇综述中,我们将讨论细胞可塑性促进再生过程的机制,以及了解和利用细胞可塑性对肠道和肝脏的潜在治疗意义。
{"title":"Cellular Plasticity in Gut and Liver Regeneration.","authors":"Minwook Kim, Yoojeong Park, You Sun Kim, Sungjin Ko","doi":"10.5009/gnl240005","DOIUrl":"10.5009/gnl240005","url":null,"abstract":"<p><p>The intestine and liver share a unique regenerative property that sets them apart from other mammalian visceral organs. The intestinal epithelium exhibits rapid renewal, making it one of the fastest renewing tissues in humans. Under physiological conditions, intestinal stem cells within each intestinal crypt continuously differentiate into the different types of intestinal epithelial cells to maintain intestinal homeostasis. However, when exposed to tissue damage or stressful conditions such as inflammation, intestinal epithelial cells in the gastrointestinal tract exhibit plasticity, allowing fully differentiated cells to regain their stem cell properties. Likewise, hepatic epithelial cells possess a remarkable regenerative capacity to restore lost liver mass through proliferation-mediated liver regeneration. When the proliferation-mediated regenerative capacity is impaired, hepatocytes and biliary epithelial cells (BECs) can undergo plasticity-mediated regeneration and replenish each other. The transition of mammalian liver progenitor cells to hepatocytes/BECs can be observed under tightly controlled experimental conditions such as severe hepatocyte injury accompanied by the loss of regenerative capacity. In this review, we will discuss the mechanism by which cellular plasticity contributes to the regeneration process and the potential therapeutic implications of understanding and harnessing cellular plasticity in the gut and liver.</p>","PeriodicalId":12885,"journal":{"name":"Gut and Liver","volume":" ","pages":"949-960"},"PeriodicalIF":3.4,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11565004/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141855366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Influence of Cytokine Genetic Polymorphisms in Helicobacter pylori-Associated Gastric Inflammation According to Sex in South Korea. 韩国不同性别的细胞因子基因多态性对幽门螺杆菌相关性胃炎的影响
IF 3.4 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-11-15 Epub Date: 2024-02-23 DOI: 10.5009/gnl230359
Hee Jin Kim, Nayoung Kim, Jae Young Jang, Sihyun Kim, Jongchan Lee, Hyeon Jeong Oh

Background/aims: : The relationship between genetic polymorphisms and gastric inflammation remains unclear. This study aimed to evaluate the impact of genetic polymorphisms on Helicobacter pylori (HP)-associated gastritis according to sex.

Methods: : Two hundred thirty-two male and 404 female subjects with current HP infection were prospectively enrolled. The genotyping of IL-1B-511 C/T, IL-1RN variable number of tandem repeats, IL-6-572 G/C, IL-8-251 A/T, IL-8-781 C/T, IL-10-1082 G/A, IL-10-592 C/A, TNF-A-308 G/A, and transforming growth factor (TGF)-B-509 C/T, was determined by polymerase chain reaction-restriction fragment length polymorphism. The degree of monocyte or neutrophil infiltration, atrophic gastritis, and intestinal metaplasia was evaluated using the updated Sydney system.

Results: : Among the male subjects, moderate/severe atrophic gastritis of the corpus was higher in IL-1B-511 CC carriers than in CT and TT carriers independent of age, alcohol consumption, and HP virulence factors (26.9% vs 10.4%; adjusted hazard ratio [HR], 4.377; 95% confidence interval, 1.387 to 13.814). In females, IL-8-251 AA carriers were independently and significantly associated with moderate/severe atrophic gastritis of the corpus compared with that in AT and TT carriers (21.4% vs 6.0%, adjusted HR=3.799). In males, the IL-8-251 TT genotype was associated with moderate/severe intestinal metaplasia of the corpus compared with the AT and AA genotypes (13.4% vs 5.6%, adjusted HR=3.128), while the IL-10-592 CA and CC genotypes were associated with moderate/severe monocyte infiltration of the antrum compared with AA genotype (83.6% vs 71.8%, adjusted HR=2.227).

Conclusions: : Genetic polymorphisms in cytokines play different roles in HP-associated gastritis according to sex.

背景/目的: :基因多态性与胃炎之间的关系仍不清楚。本研究旨在评估不同性别的基因多态性对幽门螺杆菌(HP)相关性胃炎的影响:方法:前瞻性地招募了 232 名男性和 404 名女性幽门螺杆菌感染者。通过聚合酶链式反应-限制性片段长度多态性测定了IL-1B-511 C/T、IL-1RN可变串联重复序列、IL-6-572 G/C、IL-8-251 A/T、IL-8-781 C/T、IL-10-1082 G/A、IL-10-592 C/A、TNF-A-308 G/A和转化生长因子(TGF)-B-509 C/T的基因型。采用最新的悉尼系统对单核细胞或中性粒细胞浸润、萎缩性胃炎和肠化生的程度进行了评估:在男性受试者中,IL-1B-511 CC携带者的中度/重度萎缩性胃炎高于CT和TT携带者(26.9% vs 10.4%;调整后危险比[HR]为4.377;95%置信区间为1.387至13.814),与年龄、饮酒量和HP致病因素无关。在女性中,与AT和TT携带者相比,IL-8-251 AA携带者与中度/重度萎缩性胃炎(21.4% vs 6.0%,调整后危险比=3.799)有显著的相关性。在男性中,与 AT 和 AA 基因型相比,IL-8-251 TT 基因型与胃体中度/重度肠化生相关(13.4% vs 5.6%,调整后 HR=3.128),而与 AA 基因型相比,IL-10-592 CA 和 CC 基因型与胃窦中度/重度单核细胞浸润相关(83.6% vs 71.8%,调整后 HR=2.227):细胞因子的基因多态性在HP相关性胃炎中的作用因性别而异。
{"title":"Influence of Cytokine Genetic Polymorphisms in <i>Helicobacter pylori</i>-Associated Gastric Inflammation According to Sex in South Korea.","authors":"Hee Jin Kim, Nayoung Kim, Jae Young Jang, Sihyun Kim, Jongchan Lee, Hyeon Jeong Oh","doi":"10.5009/gnl230359","DOIUrl":"10.5009/gnl230359","url":null,"abstract":"<p><strong>Background/aims: </strong>: The relationship between genetic polymorphisms and gastric inflammation remains unclear. This study aimed to evaluate the impact of genetic polymorphisms on <i>Helicobacter pylori</i> (HP)-associated gastritis according to sex.</p><p><strong>Methods: </strong>: Two hundred thirty-two male and 404 female subjects with current HP infection were prospectively enrolled. The genotyping of <i>IL-1B-511</i> C/T, <i>IL-1RN</i> variable number of tandem repeats, <i>IL-6-572</i> G/C, <i>IL-8-251</i> A/T, <i>IL-8-781</i> C/T, <i>IL-10-1082</i> G/A, <i>IL-10-592</i> C/A, <i>TNF-A-308</i> G/A, and transforming growth factor (<i>TGF</i>)-<i>B-509</i> C/T, was determined by polymerase chain reaction-restriction fragment length polymorphism. The degree of monocyte or neutrophil infiltration, atrophic gastritis, and intestinal metaplasia was evaluated using the updated Sydney system.</p><p><strong>Results: </strong>: Among the male subjects, moderate/severe atrophic gastritis of the corpus was higher in <i>IL-1B-511</i> CC carriers than in CT and TT carriers independent of age, alcohol consumption, and HP virulence factors (26.9% vs 10.4%; adjusted hazard ratio [HR], 4.377; 95% confidence interval, 1.387 to 13.814). In females, <i>IL-8-251</i> AA carriers were independently and significantly associated with moderate/severe atrophic gastritis of the corpus compared with that in AT and TT carriers (21.4% vs 6.0%, adjusted HR=3.799). In males, the <i>IL-8-251</i> TT genotype was associated with moderate/severe intestinal metaplasia of the corpus compared with the AT and AA genotypes (13.4% vs 5.6%, adjusted HR=3.128), while the <i>IL-10-592</i> CA and CC genotypes were associated with moderate/severe monocyte infiltration of the antrum compared with AA genotype (83.6% vs 71.8%, adjusted HR=2.227).</p><p><strong>Conclusions: </strong>: Genetic polymorphisms in cytokines play different roles in HP-associated gastritis according to sex.</p>","PeriodicalId":12885,"journal":{"name":"Gut and Liver","volume":" ","pages":"1002-1013"},"PeriodicalIF":3.4,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11565013/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139930863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Gut and Liver
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1